Eylea Sales Continue to Increase; Lucentis Gains New Indications

August 11, 2017: By Joan McKenna

Lucentis and EyleaRegeneron reported that its Q2-2017 net sales of Eylea in the US totaled $919 million, an increase of 11 percent over Q2-2016 net sales of $831 million.

Bayer commercializes Eylea outside the US, and its Q2-2017 net sales of the anti-VEGF increased to $542 million, up 10 percent over $486 million in Q2-2016. Regeneron said it recognized $191 million from its share of Bayer’s Eylea sales, compared with $167 million in Q2-2016.

Roche reported that Lucentis’ Q2-2017 sales in the US totaled about $348 million (CHF $335 million, conversion Aug. 11, 2017), a 5 percent decline from Q2-2016 sales. Still, revenues for the retinal treatment were up 2 percent for the first half of the year at $755 million (CHF $727 million). Roche noted that Lucentis gained US FDA approval for all forms of diabetic retinopathy during the quarter.

Novartis sells Lucentis outside the US, and its Q2-2017 sales totaled $477 million, up 5 percent in constant currency but flat in US dollars. Novartis said Lucentis has gained added labeling for choroidal neovascularization in 51 countries, as well as Europe, where the indication was approved in 2016, and the Lucentis prefilled syringe has launched in 32 countries.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Bausch + Lomb Launches Stellaris Elite for Retinal Surgery in US

Sentencing Delayed for Florida Retina Specialist Melgen

Valeant Receives FDA Complete Response Letter for Vyzulta

US FDA Clears Optovue Software for Corneal Epithelial Thickness Mapping

Ocular Therapeutix Names Daniel Bollag as Regulatory Chief

Eylea Sales Continue to Increase; Lucentis Gains New Indications

RXi Pharmaceuticals Signs Common Stock Purchase Agreement for Up to $15 Million

Allegro’s Luminate Posts Positive Results in Phase IIb Stage 2 Trial for Diabetic Macular Edema

Omeros’ Omidria Revenues Grow 71 Percent

AGTC Receives US FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigmentosa

Aerpio Shares Begin Trading on OTCQB Market

Aerie Reports FDA Concerns over Contract Manufacturer’s Plant

Valeant’s Bausch + Lomb Revenues Dip 3 percent in Q2-2017

Ocular Therapeutix Reports $66 Million in Cash, Cash Equivalents

Imprimis’ Q2-2017 Ophthalmology Revenues Increase 70 percent

Carl Zeiss Meditec’s Revenues Grow 7.5 Percent in Latest Quarter

Johnson & Johnson Vision to Acquire TearScience

Mynosys Receives $1 Million Grant from NEI to Commercialize Zepto

Ocular Therapeutix Eliminates 26 Positions; New CEO Takes Helm

Inotek Stops Development of Trabodenoson after Second Failed Study

Coming soon

2017 Glaucoma Pharmaceuticals Report: A Global Market Analysis for 2016 to 2022